These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 18940985)

  • 21. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

  • 22. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
    Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587
    [No Abstract]   [Full Text] [Related]  

  • 23. The FDA's sentinel initiative--A comprehensive approach to medical product surveillance.
    Ball R; Robb M; Anderson SA; Dal Pan G
    Clin Pharmacol Ther; 2016 Mar; 99(3):265-8. PubMed ID: 26667601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The deregulatory effects of preempting tort litigation: FDA regulation of medical devices.
    Gostin LO
    JAMA; 2008 May; 299(19):2313-6. PubMed ID: 18492972
    [No Abstract]   [Full Text] [Related]  

  • 25. Assessment of the impact of scheduled postmarketing safety summary analyses on regulatory actions.
    Sekine S; Pinnow EE; Wu E; Kurtzig R; Hall M; Dal Pan GJ
    Clin Pharmacol Ther; 2016 Jul; 100(1):102-8. PubMed ID: 26853718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Good law from tragic facts--Congress, the FDA, and preemption.
    Annas GJ
    N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
    [No Abstract]   [Full Text] [Related]  

  • 27. Medical devices; preemption of state product liability claims--FDA. Proposed rule.
    Fed Regist; 1997 Dec; 62(239):65384-8. PubMed ID: 10176832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL
    Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
    [No Abstract]   [Full Text] [Related]  

  • 29. Assessing the safety and comparative effectiveness of follow-on biologics (biosimilars) in the United States.
    Hennessy S; Leonard CE; Platt R
    Clin Pharmacol Ther; 2010 Feb; 87(2):157-9. PubMed ID: 20107450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A strike against preemption.
    Nat Biotechnol; 2009 May; 27(5):397. PubMed ID: 19430422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 32. Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012.
    Cheng CM; Shin J; Guglielmo BJ
    JAMA Intern Med; 2014 Oct; 174(10):1704-5. PubMed ID: 25127107
    [No Abstract]   [Full Text] [Related]  

  • 33. Tort reform by regulation: FDA prescription drug labeling rules and preemption of state tort claims.
    Moreland MP
    J Health Life Sci Law; 2007; 1(1):39, 41-62. PubMed ID: 18610730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Why doctors should worry about preemption.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2008 Jul; 359(1):1-3. PubMed ID: 18596269
    [No Abstract]   [Full Text] [Related]  

  • 35. Recent legal developments affecting medical device manufacturers.
    Lough MH
    Healthspan; 1993 Sep; 10(8):21-3. PubMed ID: 10129148
    [No Abstract]   [Full Text] [Related]  

  • 36. The Supreme Court, preemption, and malpractice liability.
    Kesselheim AS; Studdert DM
    N Engl J Med; 2009 Feb; 360(6):559-61. PubMed ID: 19196672
    [No Abstract]   [Full Text] [Related]  

  • 37. The risks of pharmacological therapy for insomnia (part 1): update for the clinical nurse specialist.
    O'Malley P
    Clin Nurse Spec; 2007; 21(4):188-90. PubMed ID: 17622806
    [No Abstract]   [Full Text] [Related]  

  • 38. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 39. FDA's regulation of prescription drug labeling: a role for implied preemption.
    Kendrick LC
    Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
    [No Abstract]   [Full Text] [Related]  

  • 40. Postmarketing surveillance--lack of vigilance, lack of trust.
    Fontanarosa PB; Rennie D; DeAngelis CD
    JAMA; 2004 Dec; 292(21):2647-50. PubMed ID: 15572723
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.